Scilex Holding Company provided sales guidance for the fiscal year ended December 31, 2023. For the period, the company expects total product net sales were in the range of $46.5 million to $52.5 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8805 USD | +2.29% | -1.93% | -56.84% |
Apr. 16 | Scilex Issues Preliminary Q1 Sales Results for ZTlido | MT |
Mar. 20 | Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.84% | 107M | |
+5.31% | 70.44B | |
+10.97% | 8.94B | |
-16.83% | 4.75B | |
+43.48% | 4.5B | |
+3.20% | 3.85B | |
-21.36% | 2.34B | |
-29.67% | 2.2B | |
+8.38% | 1.96B | |
+3.90% | 1.65B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023